Early treatment response assessment with [¹⁷⁷Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET.

ABSTRACT:

Background

Prostate-specific membrane antigen positron emission tomography (PSMA-PET) is an essential tool for patient selection before radioligand therapy (RLT). Interim-staging with PSMA-PET during RLT allows for therapy monitoring. However, its added value over post-treatment imaging is poorly elucidated. The aim of this study was to compare early treatment response assessed by post-therapeutic whole-body scans (WBS) with interim-staging by PSMA-PET after 2 cycles in order to prognosticate OS.

Methods

Men with metastasized castration-resistant PC (mCRPC) who had received at least two cycles of RLT, and interim PSMA-PET were evaluated retrospectively. PROMISE V2 framework was used to categorize PSMA expression and assess response to treatment. Response was defined as eithe

SUBMITTER: Ventura D 

PROVIDER: S-EPMC11414098 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature